MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

Rezdiffra
Pharma

Madrigal touts biomarker data in key MASH population

The company reported two-year biomarker results from an open-label trial arm testing Rezdiffra in patients with compensated MASH cirrhosis.
Zoey Becker May 12, 2025 2:00pm
liver

Madrigal's first-ever MASH drug beats sales projections again

May 2, 2025 11:00am
Rezdiffra

'No weakness' in Madrigal's Rezdiffra MASH launch, says CEO

Feb 27, 2025 11:19am
liver

NeuroBo Pharmaceuticals rebrands to become MetaVia

Nov 19, 2024 9:51am
liver

Amid a new MASH market, ‘tremendous change’ is on the horizon

Nov 5, 2024 10:02am
Novo Nordisk

Novo Nordisk's semaglutide delivers in phase 3 MASH study

Nov 1, 2024 10:38am